StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$6.52−0.48 (-6.86%)

Close on Nov 20, 2026Market cap $430.65MP/E –Yield –

Evolus gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Evolus's gross profit for the twelve months ending Jun 30, 2026 was $211.21M, up 13.1% year over year. For fiscal 2025 it was $197.11M, up 8.1% from the year before. The highest annual figure on record is $197.11M in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$197.11M+8.1%
FY2024Dec 31, 2024$182.30M+32.5%
FY2023Dec 31, 2023$137.57M+53.2%
FY2022Dec 31, 2022$89.77M+59.9%
FY2021Dec 31, 2021$56.14M+46.8%
FY2020Dec 31, 2020$38.24M+42.1%
FY2019Dec 31, 2019$26.91M–
FY2018Dec 31, 2018$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$57.18M+26.2%
Q1 FY2026Mar 31, 2026$48.90M+4.8%
Q4 FY2025Dec 31, 2025$59.29M+12.6%
Q3 FY2025Sep 30, 2025$45.84M+8.9%
Q2 FY2025Jun 30, 2025$45.32M-3.7%
Q1 FY2025Mar 31, 2025$46.66M+15.2%
Q4 FY2024Dec 31, 2024$52.63M+35.7%
Q3 FY2024Sep 30, 2024$42.10M+21.7%
Q2 FY2024Jun 30, 2024$47.07M+35.9%
Q1 FY2024Mar 31, 2024$40.50M+37.0%
Q4 FY2023Dec 31, 2023$38.77M+41.9%
Q3 FY2023Sep 30, 2023$34.59M+69.5%
Q2 FY2023Jun 30, 2023$34.63M+62.3%
Q1 FY2023Mar 31, 2023$29.58M+42.9%
Q4 FY2022Dec 31, 2022$27.32M+45.1%
Q3 FY2022Sep 30, 2022$20.41M+34.4%
Q2 FY2022Jun 30, 2022$21.34M+44.3%
Q1 FY2022Mar 31, 2022$20.70M+182.3%
Q4 FY2021Dec 31, 2021$18.82M+41.5%
Q3 FY2021Sep 30, 2021$15.19M+18.6%
Q2 FY2021Jun 30, 2021$14.80M+152.6%
Q1 FY2021Mar 31, 2021$7.33M+16.8%
Q4 FY2020Dec 31, 2020$13.30M-15.9%
Q3 FY2020Sep 30, 2020$12.81M+35.5%
Q2 FY2020Jun 30, 2020$5.86M+254.8%
Q1 FY2020Mar 31, 2020$6.28M–
Q4 FY2019Dec 31, 2019$15.81M–
Q3 FY2019Sep 30, 2019$9.45M–
Q2 FY2019Jun 30, 2019$1.65M–
Q1 FY2019Mar 31, 2019$0–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–

More Evolus figures

See a number that looks wrong?